Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Coronavirus / COVID-19 Pandemic -- Ignore unavailable to you. Want to Upgrade?

To: goldworldnet who wrote (1083)	4/14/2020 12:38:38 PM
From: emertius	2 Recommendations Recommended By Sam zax Read Replies (2) \| Respond to of 22884

Interesting but may I inject the thought that OMER's drug Narsoplimab (OMS721/MASP-2) is a far better choice. Soliris surpresses the immune response to infectious agents making the individual prone to secondary bacteria infection which was a major cause of death in the 1917 flu epidemic. Narsoplimab only inactivation the lectin pathway of complement activation and should not increase the risk of secondary infection. IMO Narsoplimab could be a game changer.